https://www.oncologyreviews.org/index.php/or/issue/feed Oncology Reviews 2018-07-18T21:01:13+02:00 Paola Granata paola.granata@pagepress.org Open Journal Systems <p><strong>Oncology Reviews</strong> is an Open Access, peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology.</p> <p>The journal provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. <strong>Oncology Reviews</strong> aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice.</p> <p>The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.</p> <p>The journal was previously published by Springer Italy; since 2012 <strong>Oncology Reviews</strong> passed to PAGEPress. <strong>Oncology Reviews</strong> is completely free, as it is supported by private funds.</p> https://www.oncologyreviews.org/index.php/or/article/view/352 Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update 2018-07-18T21:01:12+02:00 Luis Mendoza luis.mendoza@iqvia.com <p>Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLC). Notably, new molecular profiling technologies have permitted dynamic growth in the identification of actionable driver oncogenes including <em>RET</em> rearrangements. <em>RET</em> oncogenes cannot be adequately detected by immunohistochemistry, although fluorescence <em>in situ</em> hybridization, reverse transcriptase polymerase chain reaction and next-generation sequencing are complementary diagnostic tools. In the clinical setting, the benefit of the most developed RET inhibitors, <em>i.e</em>., cabozantinb, vandetanib and lenvatinb, in terms of response and median progression-free survival has been demonstrated. The absence of striking clinical results of RET inhibitors underscores the clear need for development of more selective and potent RET inhibitors. This paper reviews the clinical data available on RET inhibitors in RET-associated NSCLC.</p> 2018-07-10T14:40:23+02:00 ##submission.copyrightStatement## https://www.oncologyreviews.org/index.php/or/article/view/354 The radiation therapy options of intracranial hemangiopericytoma: an overview and update on a rare vascular mesenchymal tumor 2018-07-18T21:01:11+02:00 Maria Paola Ciliberti mpciliberti@libero.it Rosa D'Agostino rosa.dago.rd@gmail.com Laura Gabrieli gabrielilaura@gmail.com Anna Nikolaou annanikolaou@hotmail.it Angela Sardaro angela.sardaro@uniba.it <p>Hemangiopericytoma (HPC) is an extremely rare hypervascular tumor of mesenchymal lineage. It tends to recur and to develop distant metastases even many years after primary surgical resection. The management of recurrent and metastatic disease is not always so well defined. A complete surgical resection does not eliminate the high risk of local recurrences that occur in the central nervous system, often in the same surgical bed. However, treatment with adjuvant radiotherapy even in cases of complete resection remains controversial.</p> 2018-07-10T15:23:45+02:00 ##submission.copyrightStatement## https://www.oncologyreviews.org/index.php/or/article/view/374 Treat patient, not just the disease: holistic needs assessment for haematological cancer patients 2018-07-18T21:01:13+02:00 Md Serajul Islam serajul@doctors.org.uk <p>Haematological malignancies can have devastating on the patients’ physical, emotional, psycho-sexual, educational and economic health. With the improvement of therapies patients with these malignancies are living longer, however significant proportion these patient show poor quality of life (QoL) due to various physical and psychological consequences of the disease and the treatments. Health-related QoL (HRQoL) is multi-dimensional and temporal, relating to a state of functional, physical, psychological and social/family well-being. Compared with the general population, HRQoL of these patients is worse in most dimensions. However without routine holistic need assessment (HNA), clinicians are unlikely to identify patients with clinically significant distress. Surviving cancer is a chronic lifealtering condition with several factors negatively affecting their QoL, such as psychological problems, including depression and excessive fear of recurrence, as well as social aspects, such as unemployment and social isolation. These need to be adequately understood and addressed in the healthcare of long-term survivors of haematological cancer. Applying a holistic approach to patient care has many benefits and yet, only around 25% of cancer survivors in the UK receive a holistic needs assessment. The efforts of the last decade have established the importance of ensuring access to psychosocial services for haematological cancer survivors. We need to determine the most effective practices and how best to deliver them across diverse settings. Distress, like haematological cancer, is not a single entity, and one treatment does not fit all. Psychosocial-oncology needs to increase its research in comparative effectiveness.</p> 2018-07-04T14:41:38+02:00 ##submission.copyrightStatement## https://www.oncologyreviews.org/index.php/or/article/view/356 Testosterone, prolactin, and oncogenic regulation of the prostate gland. A new concept: Testosterone-independent malignancy is the development of prolactin-dependent malignancy! 2018-07-18T21:01:13+02:00 Leslie C. Costello lcostello@umaryland.edu Renty B. Franklin rfranklin@umaryland.edu <p>Hormone-independent malignancy is a major issue of morbidity and deaths that confronts prostate cancer. Despite decades of research, the oncogenic and hormonal implications in the development and progression of prostate malignancy remain mostly speculative. This is largely due to the absence and/or lack of consideration by contemporary clinicians and biomedical investigators regarding the established implications of the co-regulation of testosterone and prolactin in the development, maintenance, metabolism and functions of the prostate gland. Especially relevant is the major metabolic function of production of high levels of citrate by the peripheral zone acinar epithelial cells. Citrate production, along with growth and proliferation by these cells, is regulated by co-existing testosterone and prolactin signaling pathways; and by the oncogenic down-regulation of ZIP1 transporter/zinc/citrate in the development of malignancy. These relationships had not been considered in the issues of hormone-dependent malignancy. This review provides the relevant background that has established the dual role of testosterone and prolactin regulation of the prostate gland; which is essential to address the implications in the oncogenic development and progression of hormone-dependent malignancy. The oncogenic factor along with testosterone-dependent and prolactin-dependent relationships leads to the plausible concept that androgen ablation for the treatment of testosterone-dependent malignancy results in the development of prolactin-dependent malignancy; which is testosterone-independent malignancy. Consequently, both testosterone ablation and prolactin ablation are required to prevent and/or abort terminal hormonedependent prostate cancer.</p> 2018-07-04T16:03:25+02:00 ##submission.copyrightStatement##